Embracing the Transformative Role of AI in Driving RWD Adoption

Real-world data (RWD) and real-world evidence (RWE) are playing an increasingly important role across the pharmaceutical research and development lifecycle, as life sciences organizations look to strengthen evidence generation, improve efficiency and support patient safety. Drawing in part on new industry research from the Tufts Center for the Study of Drug Development (Tufts CSDD), this webinar examines how RWD and RWE are being adopted across the industry and where opportunities for broader impact remain.

Advances in AI are expanding access to RWD, enabling researchers to improve study design, optimize site selection, strengthen patient recruitment and support patient safety initiatives. Life sciences organizations are applying RWD and RWE across multiple use cases, including retrospective and prospective studies, comparative effectiveness research, health economics and outcomes research and commercialization.

However, data volume and computing power alone do not ensure better decisions. Translating RWD into evidentiary insight depends on data quality, governance and close collaboration between medical and technical experts. This webinar highlights current adoption patterns, practical constraints and opportunities to generate actionable insight across the drug development lifecycle.

This webinar will feature a discussion that includes:

• The role AI can play in the curation and analysis of real-world data and its impact on the drug development lifecycle
• Use cases for RWD/RWE beyond clinical trial optimization, patient recruitment and pharmacovigilance
• Current industry adoption in terms of use cases and potential for expansion, challenges/opportunities and ROI
• Data sources beyond EHR patient records, the industry is looking to leverage in the curation of RWD

Register for this webinar to learn how RWD can be transformed into high-quality RWE that supports better decision-making across pharmaceutical research and development.

Speakers

Ken Getz, Executive Director & Research Professor, Tufts Center for the Study of Drug Development

Ken Getz is the Executive Director of the Tufts Center for the Study of Drug Development and a Research Professor at the Tufts University School of Medicine. He is an internationally recognized expert on pharmaceutical R&D management and execution, protocol design, contract service provider and investigative site management, eClinical technology and data usage and patient engagement.

A well-known speaker at conferences, symposia, universities, investor meetings and corporations, Ken has published extensively in peer-reviewed journals, books and the trade press. He holds several board appointments in the private and public sectors. He received his MBA from the J.L. Kellogg Graduate School of Management at Northwestern University and a bachelor’s degree from Brandeis University.

Ken is also the chairman of CISCRP, a nonprofit organization he founded to educate and raise public and patient awareness of the clinical research enterprise, and the founder of CenterWatch, a leading publisher in the clinical trials industry and of several other businesses he has sold. Learn more

Message Presenter

Aracelis Torres, PhD, MPH, Chief Data & Science Officer, Verana Health

Aracelis Torres, PhD, MPH, is Chief Data & Science Officer, where she oversees the Quantitative Sciences team working on rigorous methodology to generate sound scientific evidence from real-world data, as well as the commercial services and operations team that manages client deliverables.

Dr. Torres is an Epidemiologist with over ten years of academic and industry experience. Prior to joining Verana Health, she was a Director of Quantitative Sciences at Flatiron Health, where her work focused on translating real-world oncology data to generate evidence. While at Flatiron Health, she led efforts related to the development of real-world endpoints, novel study designs and prospective evidence generation while also serving as the Quantitative Sciences lead for the organization’s broader research collaboration with the FDA. She is also currently an Adjunct Professor at Columbia University Graduate School of Arts and Sciences, where she teaches a course on large-scale data processing and analysis.

Dr. Torres received a PhD in Cancer Epidemiology from Johns Hopkins Bloomberg School of Public Health, an MPH in Chronic Disease Epidemiology from Yale University’s School of Public Health and a BS in Molecular, Cellular and Developmental Biology from Yale University.

Message Presenter